# NEUROCRINE BIOSCIENCES INC (NBIX) — capital_raise [announced]
Source: SEC API (secapi.ai) · situation sit_a1e4ed39a6e380e4125e · retrieved 2026-08-11T16:15:05.842Z

## Overview
Neurocrine Biosciences is a leading biopharmaceutical company dedicated to discovering, developing and commercializing life-changing treatments for patients with neurological, psychiatric, endocrine and immunological disorders; its portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in…

Neurocrine Biosciences completed its acquisition of Soleno Therapeutics in May 2026 for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. The acquisition adds VYKAT XR, a first-in-class therapy to treat hyperphagia in Prader-Willi syndrome, expanding Neurocrine's portfolio of innovative medicines and strengthening its leadership position in endocrinology and rare disease.

## Terms
- Counterparty: Soleno Therapeutics · Deal value: $2.90B · Consideration: cash · Price/share: $53

## Key dates
- Announced 2026-07-30

## Timeline
- 2026-07-30 · 8-K (0000914475-26-000035): 8-K - NEUROCRINE BIOSCIENCES INC — *Neurocrine Biosciences is a leading biopharmaceutical company dedicated to discovering, developing and commercializing life-changing treatments for patients with neurological, psychiatric, endocrine and immunological disorders; its portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in…* Neurocrine Biosciences completed its acquisition of Soleno Therapeutics in May 2026 for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. The acquisition adds VYKAT XR, a first-in-class therapy to treat hyperphagia in Prader-Willi syndrome, expanding Neurocrine's portfolio of innovative medicines and strengthening its leadership position in endocrinology and rare disease.
  https://www.sec.gov/Archives/edgar/data/914475/0000914475-26-000035.txt

## Citations
- 0000914475-26-000035 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000091447526000035